TAP Prevacid pediatric indication
This article was originally published in Pharmaceutical Approvals Monthly
TAP's proton pump inhibitor Prevacid (lansoprazole) clears FDA July 31 for the short-term treatment of symptomatic gastroesophageal reflux disease and erosive esophagitis in children one to 11 years old. The Abbott/Takeda joint venture is highlighting Prevacid as the only PPI available in an oral suspension formulation, a potential advantage for children who have difficulty swallowing capsule
You may also be interested in...
China’s first domestically-developed recombinant protein vaccine for COVID-19 moves forward in late-stage trials in two countries.
Splitting Colfax into separate fabrication technology and specialty medical technology businesses will help both sides of the business grow, CEO Matthew Trerotola said recently.
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This selection of recent insights from our experienced on-the-ground team will help.